Diseases are becoming more virulent and thus are more difficult to treat and cure. Despite advances on the pharmaceutical front, human health is under unprecedented threat in the face of the deteriorating environment. Searching for solutions to enhance the health of the human race is the mission of any pharmaceutical company. Obio strives to be one of the leading research companies in the pharmaceutical industry, specializing in globally concerned diseases and health issues.
 
Type 2 Diabetes is a metabolic disorder that is primarily characterized by insulin problems. The main cause of this disease is insufficient exercise and imbalance diet. It is common to be found in African Americans, Latinos, but is now rapidly increasing in the developed world due to obesity. It used to be found mostly in adults aged above 45, but is now increasingly appearing in children and adolescents.
 
 
Influenza is divided into 3 types: A, B and C. Type A influenza includes most human and all avian influenza viruses.
Avian influenza viruses can be divided into highly pathogenic (HPAI) and low pathogenic (LPAI) strains based on its ability to cause disease in poultry. The H5N1 virus is the strain of avian influenza that has infected numerous species of birds in Asia, Europe and Africa since the end of 2003.
 
 
Obio Pharmaceutical社、製品成長戦略...
read more
 
 
Obio Pharmaceutical Announces Product Growth...
read more
 
 
Obio Pharmaceutical Announced New Antiviral ...
read more
 
 
Obio Pharmaceutical Announced Appointment of ...
read more
 
 
A new case of human infection of H5N1 avian i...
read more